Results 101 to 110 of about 14,070 (188)

Persistent Acral Pityriasis Rosea in a Pediatric Patient: A Rare Clinical Variant. [PDF]

Cureus
Alsemairi LT, Alghamdi AS, Alghamdi M, Alghamdi A, Alghamdi S, Alzahrani M.   +5 more
europepmc   +1 more source

Amoxicillin-Clavulanate-Induced Pityriasis Rosea: A Pharmacovigilance Case Report. [PDF]

Cureus
Franz C, Handa D, Joseph G, Bhatti N, Badyal DK.   +4 more
europepmc   +1 more source

Line-field confocal optical coherence tomography assessment of pityriasis rosea. [PDF]

JAAD Case Rep, 2023
Pathak GN, Truong TM, Rao BK.
europepmc   +1 more source

Purpuric pityriasis rosea in a 7-year-old girl: A rare variant with generalized involvement. [PDF]

JAAD Case Rep
Qian YY, Wu YF, Zhang T, Li JB, Song SY, Li W.   +5 more
europepmc   +1 more source

The use of antivirals in severe or recalcitrant cases of pityriasis rosea: A case series

JAAD Case Reports, 2022
Lihi Tzur, MD, Fei-Shiuann Yang, MD, Sandhya Deverapalli, MD   +2 more
doaj   +1 more source

Pityriasis rosea manifesting only with a herald patch. [PDF]

Dermatol Reports
Drago F, Varesano S, Herzum A, Ciccarese G.   +3 more
europepmc   +1 more source

The risks of pityriasis rosea in pregnancy: a review. [PDF]

Int J Womens Dermatol
Manduca S, Oh CS, Ong M, Lipner SR, Pomeranz MK, Bieber AK.   +5 more
europepmc   +1 more source

Reply to "Pityriasis rosea during COVID-19 and its pathogenesis". [PDF]

JAAD Int, 2022
Nussbaum D, Wei C, Pakhchanian H, Raiker R, Liu IZ, Friedman A.   +5 more
europepmc   +1 more source

Pityriasis rosea associated with imatinib (STI571,Gleevec)

, 2002
A tyrosine kinase inhibitor (STI571, Gleevec) has recently been applied in the treatment of chronic myeloid leukemia. We present the first reported case of pityriasis rosea occurring as a reaction to Gleevec in a woman with blast crisis of this disorder.
Meletis, J, Konstantopoulos, K, Papadogianni, A, Dimopoulou, M, Kourelis, C   +4 more
core  

Purpuric pityriasis rosea in patients with anorexia nervosa. [PDF]

Dermatol Reports
Ciccarese G, Guadagno A, Herzum A, Amicarelli V, Drago F.   +4 more
europepmc   +1 more source